Suppr超能文献

肝硬化病因的变化及相应的管理策略。

Changes in the etiology of liver cirrhosis and the corresponding management strategies.

作者信息

Dai Jin-Jin, Liu Yue-Ying, Zhang Zhen-Hua

机构信息

Department of Infectious Diseases, Suzhou Hospital of Anhui Medical University, Suzhou 234000, Anhui Province, China.

Department of Infectious Diseases, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China.

出版信息

World J Hepatol. 2024 Feb 27;16(2):146-151. doi: 10.4254/wjh.v16.i2.146.

Abstract

We read with interest the article by Xing Wang, which was published in the recent issue of the 2023; 15: 1294-1306. This article focuses particularly on the prevalence and trends in the etiology of liver cirrhosis (LC), prognosis for patients suffering from cirrhosis-related complications and hepatocellular carcinoma (HCC), and management strategies. The etiology of cirrhosis varies according to geographical, economic, and population factors. Viral hepatitis is the dominant cause in China. Vaccination and effective treatment have reduced the number of people with viral hepatitis, but the overall number is still large. Patients with viral hepatitis who progress over time to LC and HCC remain an important population to manage. The increased incidence of metabolic syndrome and alcohol consumption is likely to lead to a potential exponential increase in metabolic dysfunction-associated steatotic liver disease (MASLD)-associated LC and alcoholic liver disease in the future. Investigating the evolution of the etiology of LC is important for guiding the direction of future research and policy development. These changing trends indicate a need for greater emphasis on tackling obesity and diabetes, and implementing more effective measures to regulate alcohol consumption in order to reduce the occurrence of MASLD. In an effort to help cope with these changing trends, the authors further proposed countermeasures for healthcare authorities doctors, and patients.

摘要

我们饶有兴趣地阅读了王兴发表在最近一期《2023;15:1294 - 1306》上的文章。本文特别关注肝硬化(LC)病因的流行情况和趋势、肝硬化相关并发症和肝细胞癌(HCC)患者的预后以及管理策略。肝硬化的病因因地理、经济和人口因素而异。在中国,病毒性肝炎是主要病因。疫苗接种和有效治疗已减少了病毒性肝炎患者的数量,但总体数量仍然很大。随着时间推移进展为LC和HCC的病毒性肝炎患者仍是需要管理的重要人群。代谢综合征和酒精消费的增加可能会导致未来代谢功能障碍相关脂肪性肝病(MASLD)相关的LC和酒精性肝病潜在呈指数增长。研究LC病因的演变对于指导未来研究方向和政策制定很重要。这些不断变化的趋势表明需要更加重视解决肥胖和糖尿病问题,并采取更有效的措施来规范酒精消费,以减少MASLD的发生。为了帮助应对这些不断变化的趋势,作者进一步为卫生当局、医生和患者提出了对策。

相似文献

2
Study of liver cirrhosis over ten consecutive years in Southern China.中国南方地区连续十年肝硬化研究。
World J Gastroenterol. 2014 Oct 7;20(37):13546-55. doi: 10.3748/wjg.v20.i37.13546.
5
Overview of Complications in Cirrhosis.肝硬化并发症概述
J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1150-1174. doi: 10.1016/j.jceh.2022.04.021. Epub 2022 May 14.

本文引用的文献

2
Autoimmune Hepatitis: Epidemiology, Subtypes, and Presentation.自身免疫性肝炎:流行病学、亚型和表现。
Clin Liver Dis. 2024 Feb;28(1):1-14. doi: 10.1016/j.cld.2023.06.002. Epub 2023 Aug 17.
5
Overview and countermeasures of cancer burden in China.中国癌症负担概述及对策。
Sci China Life Sci. 2023 Nov;66(11):2515-2526. doi: 10.1007/s11427-022-2240-6. Epub 2023 Apr 13.
6
Global burden of liver disease: 2023 update.全球肝病负担:2023 年更新。
J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27.
7
Contemporary Epidemiology of Primary Biliary Cholangitis.原发性胆汁性胆管炎的当代流行病学。
Clin Liver Dis. 2022 Nov;26(4):555-570. doi: 10.1016/j.cld.2022.06.001. Epub 2022 Sep 11.
8
Global burden of primary liver cancer in 2020 and predictions to 2040.2020 年全球原发性肝癌负担及 2040 年预测。
J Hepatol. 2022 Dec;77(6):1598-1606. doi: 10.1016/j.jhep.2022.08.021. Epub 2022 Oct 5.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验